A PHASE 3, MULTICENTER, FOUR-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY TRIAL OF FLEXIBLE DOSES OF ORAL ZIPRASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR I DISORDER (CURRENT OR MOST RECENT EPISODE MANIC)
Phase of Trial: Phase III
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Ziprasidone (Primary)
- Indications Bipolar I disorders
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 24 Sep 2019 Planned End Date changed from 5 Oct 2020 to 6 Jan 2021.
- 24 Sep 2019 Planned primary completion date changed from 3 Sep 2020 to 30 Nov 2020.
- 19 Mar 2019 Planned number of patients changed from 180 to 194.